Synedgen’s current lead asset is MIIST305, a clinic-ready, orally delivered therapeutic that repairs GI mucosal injury. MIIST305 restores GI function and reduces unchecked inflammation and damage.
Learn about MIIST305Targeted therapies
Scalable GMP production
Excellent safety profiles
Strong IP Position
Synedgen's therapeutics have demonstrated efficacy across multiple modalities
See our full portfolio